To amend the Public Health Service Act to establish insulin assistance programs, and for other purposes.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
The bill creates insulin assistance programs, creates insulin assistance programs for eligible individuals, and expands deductibles and other out-of-pocket expenses for underinsured individuals participating in insulin assistance programs. It relies on tax rate changes, grants, compliance mandates, and tax deductions. The main policy areas are Trade, Healthcare, and Finance.
Who Benefits and How
Eligible Individuals (uninsured or underinsured) could see lower costs, Pharmaceutical Companies could gain revenue opportunities, and Insulin Manufacturers could gain revenue opportunities.
Who Bears the Burden and How
Holders of approved applications or licenses for insulin products (applicable entities) could face higher costs.
Key Provisions
- Creates insulin assistance programs.
- Creates insulin assistance programs for eligible individuals.
- Expands deductibles and other out-of-pocket expenses for underinsured individuals participating in insulin assistance programs.
- Creates annual fees applicable to insulin manufacturers.
- Requires identification of insulin price spikes; application of excise tax.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill creates insulin assistance programs, creates insulin assistance programs for eligible individuals, and expands deductibles and other out-of-pocket expenses for underinsured individuals participating in insulin assistance programs.
Key Policy Areas
Trade, Healthcare, Finance
Primary Purpose
The bill creates insulin assistance programs, creates insulin assistance programs for eligible individuals, and expands deductibles and other out-of-pocket expenses for underinsured individuals participating in insulin assistance programs.
Policy Domains
Whole bill
Identified Gains
- Eligible Individuals (uninsured or underinsured)
- Pharmaceutical Companies
- Insulin Manufacturers
- Underinsured Individuals with High-Deductible Health Plans
Identified Costs
- Holders of approved applications or licenses for insulin products (applicable entities)
Sponsors
Legislative Progress
IntroducedMs. Smith introduced the following bill; which was read twice …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Holders of approved applications or licenses for insulin products (applicable entities), Pharmaceutical Companies
Positive-direction: Pharmaceutical Companies
Negative-direction: Holders of approved applications or licenses for insulin products (applicable entities)
Eligible individuals (uninsured or underinsured)
Insulin Manufacturers, Insulin Product Manufacturers
Underinsured Individuals with High-Deductible Health Plans
States, Indian tribes, and tribal organizations
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology